KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Income (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Net Income for 15 consecutive years, with $24.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 617775.0% year-over-year to $24.7 million, compared with a TTM value of $24.7 million through Dec 2025, up 2801.09%, and an annual FY2025 reading of $24.7 million, up 2801.09% over the prior year.
  • Net Income was $24.7 million for Q4 2025 at Travere Therapeutics, up from $4000.0 in the prior quarter.
  • Across five years, Net Income topped out at $240.0 million in Q3 2023 and bottomed at -$88.8 million in Q4 2021.
  • Average Net Income over 5 years is $7.3 million, with a median of $4000.0 recorded in 2024.
  • The sharpest move saw Net Income plummeted 6766.71% in 2021, then skyrocketed 617775.0% in 2025.
  • Year by year, Net Income stood at -$88.8 million in 2021, then surged by 122.32% to $19.8 million in 2022, then crashed by 107.96% to -$1.6 million in 2023, then skyrocketed by 100.25% to $4000.0 in 2024, then surged by 617775.0% to $24.7 million in 2025.
  • Business Quant data shows Net Income for TVTX at $24.7 million in Q4 2025, $4000.0 in Q4 2024, and -$59000.0 in Q3 2024.